We evaluated morbidity and mortality among individuals first starting antiretroviral therapy ( ART ) with concurrent active TB or other AIDS-defining disease using data from the `` Prospective Evaluation of Antiretrovirals in Resource-Limited Settings '' ( PEARLS ) study .